Caribou Biosciences financials
$1.23−0.81%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $2.4M | $3.9M | $2.2M | $2.7M | $2.4M | $2.1M | $2.0M | $3.5M | $2.4M | $3.6M | $23.7M |
| Gross profit | $1.5M | $2.4M | $3.9M | $2.2M | $2.7M | $2.4M | $2.1M | $2.0M | $3.5M | $2.4M | $3.6M | $23.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$25.3M | -$26.3M | -$28.5M | -$29.4M | -$47.6M | -$42.9M | -$38.9M | -$38.2M | -$43.5M | -$46.0M | -$37.4M | -$14.6M |
| Net income | -$24.3M | -$25.1M | -$26.6M | -$27.5M | -$54.1M | -$40.0M | -$35.3M | -$34.7M | -$37.7M | -$41.2M | -$34.5M | -$10.0M |
| Net margin | −1619.9% | −1046.5% | −676.0% | −1253.3% | −2028.4% | −1699.6% | −1697.9% | −1713.6% | −1088.3% | −1697.6% | −969.8% | −42.3% |
| Diluted EPS | $-0.24 | $-0.26 | $-0.28 | $-0.30 | $-0.58 | $-0.43 | $-0.39 | $-0.38 | $-0.42 | $-0.46 | $-0.39 | $-0.12 |
| EBITDA | -$24.7M | -$25.6M | -$27.8M | -$28.8M | -$34.3M | -$41.7M | -$37.7M | -$37.1M | -$42.6M | -$45.3M | -$36.7M | -$13.1M |
| Operating cash flow | -$22.8M | -$27.0M | -$20.8M | -$25.2M | -$28.3M | -$36.7M | -$35.5M | -$32.7M | -$32.9M | -$37.2M | -$21.4M | -$28.8M |
| Free cash flow | -$22.8M | -$27.1M | -$21.0M | -$25.3M | -$28.7M | -$37.8M | -$36.0M | -$33.3M | -$33.6M | -$40.2M | -$23.7M | -$33.5M |
| Diluted shares | 101.0M | 95.9M | 94.6M | 93.3M | 93.0M | 92.7M | 91.2M | 90.5M | 90.3M | 89.3M | 88.8M | 83.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.2M | $12.1M | $12.4M | $11.1M | $25.2M | $29.4M |
| Short-term investments | $86.1M | $105.6M | $127.0M | $136.1M | $158.7M | $179.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $142.8M | $149.0M | $175.4M | $195.0M | $220.9M | $273.7M |
| Total liabilities | $44.7M | $47.0M | $53.2M | $53.1M | $54.8M | $56.4M |
| Shareholders' equity | $98.1M | $102.0M | $122.2M | $141.8M | $166.1M | $217.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology